Intestinal microbiome ecosystem (Gut microbiome)

The intestinal microbiome ecosystem refers to the complex community of trillions of microorganisms, including bacteria, fungi, viruses, and archaea, residing in the human gastrointestinal tract. This ecosystem functions as a virtual organ, playing a critical role in host digestion, the synthesis of essential vitamins, and the development and regulation of the systemic immune system [1][2]. Dysbiosis, or the functional imbalance of this microbial community, is strongly linked to a wide array of local and systemic pathologies, ranging from Clostridioides difficile infections and inflammatory bowel disease to metabolic syndromes and even neurological conditions via the gut-brain axis [3][4]. Therapeutic targeting of the intestinal microbiome has evolved from broad-spectrum antibiotics to more precise interventions such as fecal microbiota transplantation (FMT), live biotherapeutic products (LBPs), and prebiotics designed to selectively foster beneficial taxa [5]. Recent FDA approvals of standardized microbiota-based therapies like Vowst and Rebyota mark a shift toward treating the ecosystem as a cohesive pharmacological target to restore colonization resistance and metabolic homeostasis [6]. Understanding the specific interactions between microbial metabolites and host receptors remains a primary focus for developing next-generation precision microbiome-modulating drugs [7]. Sources: [1] NIH Human Microbiome Project; [2] Nature Reviews Microbiology (2022); [3] Cell (2020); [4] Science (2021); [5] Gastroenterology (2023); [6] FDA Drug Approvals (2023); [7] Journal of Clinical Investigation (2022).

Other names

Gut microbiotaIntestinal floraGastrointestinal microbiomeGut microflora

Restoration of microbial diversity and ecological balance; competitive exclusion of pathogenic species; modulation of host immune responses through toll-like receptor (TLR) signaling; production of bioactive metabolites like butyrate that maintain epithelial barrier integrity.